Kintor Pharma IPO: Valuation Insights
Kintor Pharmaceutical (9939 HK) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers and...
334 Views
Kintor Pharma IPO Initiation: To Screen, or Not to Screen?
Kintor Pharmaceutical (1762178D CH) is a clinical-stage drug developer with a focus on potential first-in-class and best-in-class drugs for cancers...
281 Views
ECM Weekly (26 Apr 2020) - Kingsoft Cloud, WeDoctor, Akesobio, Kotak Mahindra Bank
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Akeso...
385 Views
Akesobio: Trading Debut, Valuation Scenario Analysis
Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...
473 Views
Akesobio (康方生物) IPO Trading: Action Post Near Zero Allocation
Akesobio, a China-based biotech company, raised USD 314 million at HKD 16.18 per share. The deal has attracted strong demands from both retail...
432 Views